Compare ERII & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | PRME |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 536.4M |
| IPO Year | 2008 | 2022 |
| Metric | ERII | PRME |
|---|---|---|
| Price | $8.11 | $3.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.07 | $7.56 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.00 | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,987,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $20.55 | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $8.14 | $1.18 |
| 52 Week High | $18.31 | $6.94 |
| Indicator | ERII | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 59.16 |
| Support Level | N/A | $3.15 |
| Resistance Level | $11.58 | $3.60 |
| Average True Range (ATR) | 0.42 | 0.23 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 1.61 | 93.44 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.